Patents by Inventor Joelle Lorraine Burgess
Joelle Lorraine Burgess has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10478426Abstract: This invention relates to novel substituted benzamide according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.Type: GrantFiled: March 20, 2018Date of Patent: November 19, 2019Assignee: GLAXOSMITHKLINE LLCInventors: Joelle Lorraine Burgess, Steven David Knight
-
Publication number: 20180207144Abstract: This invention relates to novel substituted benzamide according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.Type: ApplicationFiled: March 20, 2018Publication date: July 26, 2018Inventors: Joelle Lorraine BURGESS, Steven David KNIGHT
-
Patent number: 9956210Abstract: This invention relates to novel substituted benzamide according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.Type: GrantFiled: December 15, 2016Date of Patent: May 1, 2018Assignee: GLAXOSMITHKLINE LLCInventors: Joelle Lorraine Burgess, Steven David Knight
-
Patent number: 9790212Abstract: This invention relates to novel compounds according to Formula (III)(a) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), and to pharmaceutical compositions containing them.Type: GrantFiled: October 13, 2016Date of Patent: October 17, 2017Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITEDInventors: Charles William Blackledge, Jr., Joelle Lorraine Burgess, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Louis V. LaFrance, III, Juan I. Luengo, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Mark Schulz, Dai-Shi Su, Xinrong Tian
-
Publication number: 20170095461Abstract: This invention relates to novel substituted benzamide according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.Type: ApplicationFiled: December 15, 2016Publication date: April 6, 2017Inventors: Joelle Lorraine Burgess, Steven David Knight
-
Patent number: 9562041Abstract: This invention relates to novel substituted benzamides according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.Type: GrantFiled: May 15, 2013Date of Patent: February 7, 2017Assignee: GlaxoSmithKline LLCInventors: Joelle Lorraine Burgess, Steven David Knight
-
Publication number: 20170029412Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.Type: ApplicationFiled: October 13, 2016Publication date: February 2, 2017Inventors: Charles William BLACKLEDGE, JR., Joelle Lorraine BURGESS, Neil W. JOHNSON, Jiri KASPAREC, Steven David KNIGHT, Louis V. LaFRANCE, III, Juan I. LUENGO, William Henry MILLER, Kenneth Allen NEWLANDER, Stuart Paul ROMERIL, Mark SCHULZ, Dai-Shi SU, Xinrong TIAN
-
Patent number: 9556157Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.Type: GrantFiled: July 9, 2014Date of Patent: January 31, 2017Assignee: GlaxoSmithKline Intellectual Property (No.2) LimitedInventors: Joelle Lorraine Burgess, Steven David Knight
-
Patent number: 9505745Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.Type: GrantFiled: April 25, 2014Date of Patent: November 29, 2016Assignee: GlaxoSmithKline Intellectual Property (No. 2) LimitedInventors: Charles William Blackledge, Jr., Joelle Lorraine Burgess, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Louis V. LaFrance, III, Juan I. Luengo, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Mark Schulz, Dai-Shi Su, Xinrong Tian
-
Patent number: 9402836Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.Type: GrantFiled: July 9, 2015Date of Patent: August 2, 2016Assignee: GlaxoSmithKline LLCInventors: James Brackley, III, Joelle Lorraine Burgess, Seth Wilson Grant, Neil W. Johnson, Steven David Knight, Louis Vincent LaFrance, III, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Meagan B. Rouse, Xinrong Tian, Sharad Kumar Verma
-
Publication number: 20160130261Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.Type: ApplicationFiled: July 9, 2014Publication date: May 12, 2016Inventors: Joelle Lorraine BURGESS, Steven David KNIGHT
-
Publication number: 20160102083Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.Type: ApplicationFiled: April 25, 2014Publication date: April 14, 2016Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITEDInventors: Charles William BLACKLEDGE, JR., Joelle Lorraine BURGESS, Neil W. JOHNSON, Jiri KASPAREC, Steven David KNIGHT, Louis V. LaFRANCE, III, Juan I. LUENGO, William Henry MILLER, Kenneth Allen NEWLANDER, Stuart Paul ROMERIL, Mark SCHULZ, Dai-Shi SU, Xinrong TIAN
-
Publication number: 20150313887Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.Type: ApplicationFiled: July 9, 2015Publication date: November 5, 2015Inventors: James BRACKLEY, III, Joelle Lorraine Burgess, Seth Wilson Grant, Neil W. Johnson, Steven David Knight, Louis Vincent LaFrance, III, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Meagan B. Rouse, Xinrong Tian, Sharad Kumar Verma
-
Patent number: 9073924Abstract: Herein are disclosed azaindazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.Type: GrantFiled: September 12, 2012Date of Patent: July 7, 2015Assignee: GlaxoSmithKline LLCInventors: Joelle Lorraine Burgess, Neil W. Johnson, Steven David Knight, Louis Vincent LaFrance, III, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Meagan B. Rouse, Dominic Suarez, Xinrong Tian, Sharad Kumar Verma
-
Publication number: 20150126522Abstract: This invention relates to novel substituted benzamides according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.Type: ApplicationFiled: May 15, 2013Publication date: May 7, 2015Applicant: GlaxoSmithKline LLCInventors: Joelle Lorraine Burgess, Celine Duquenne, Steven David Knight, William Henry Miller, Kenneth Allen Newlander, Sharad Kumar Verma
-
Patent number: 8975291Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.Type: GrantFiled: August 7, 2013Date of Patent: March 10, 2015Assignee: GlaxoSmithKline LLCInventors: James Brackley, III, Joelle Lorraine Burgess, Seth Grant, Neil Johnson, Steven D. Knight, Louis Lafrance, William H. Miller, Kenneth Newlander, Stuart Romeril, Meagan B. Rouse, Xinrong Tian, Sharad Kumar Verma
-
Publication number: 20140343056Abstract: Herein are disclosed azaindazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.Type: ApplicationFiled: September 12, 2012Publication date: November 20, 2014Applicant: GlaxoSmithKline LLCInventors: Joelle Lorraine Burgess, Neil W. Johnson, Steven David Knight, Louis Vincent LaFrance, III, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Meagan B. Rouse, Dominic Suarez, Xinrong Tian, Sharad Kumar Verma
-
Publication number: 20140296224Abstract: Invented is a method of inhibiting the activity/function of PI3 kinases using quinoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoline derivatives.Type: ApplicationFiled: June 17, 2014Publication date: October 2, 2014Inventors: Nicholas D. ADAMS, Joelle Lorraine Burgess, Michael Gerard Darcy, Carla A. Donatelli, Steven David Knight, Kenneth Allen Newlander, Lance Ridgers, Martha A. Sarpong, Stanley J. Schmidt
-
Patent number: 8637509Abstract: Herein are disclosed azaindazoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.Type: GrantFiled: May 5, 2011Date of Patent: January 28, 2014Assignee: GlaxoSmithKline LLCInventors: Joelle Lorraine Burgess, Neil Johnson, Steven D. Knight, Louis LaFrance, William H. Miller, Kenneth Newlander, Stuart Romeril, Meagan B. Rouse, Xinrong Tian, Sharad Kumar Verma, Dominic Suarez
-
Publication number: 20130345200Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.Type: ApplicationFiled: August 7, 2013Publication date: December 26, 2013Applicant: GlaxoSmithKline LLCInventors: James Brackley, III, Joelle Lorraine Burgess, Seth Grant, Neil Johnson, Steven D. Knight, Louis Lafrance, William H. Miller, Kenneth Newlander, Stuart Romeril, Meagan B. Rouse, Xinrong Tian, Sharad Kumar Verma